Abstract
Over the last two decades, SPECT (single photon emission computed tomography) and especially PET (positron emission tomography) have proven increasingly effective imaging modalities in the study of human psychopharmacology. Abusing populations can be studied at multiple times after abstinence begins, to give information about neurochemical and physiological adaptations of the brain during recovery from addiction. Individual human subjects can be studied using multiple positron labeled radiotracers, so as to probe more than one facet of brain function. PET and SPECT have been used to help our understanding of many aspects of the pharmacokinetics and pharmacodynamics of abused drugs, and have made valuable contributions in terms of drug mechanisms, drug interactions (e.g. cocaine and alcohol) and drug toxicities. They have also been employed to study the acute effects of drugs on populations of active drug abusers and of normal controls, and to evaluate the neurochemical consequences of candidate therapies for drug abuse. A particularly productive strategy has been the use of PET in conjunction with neuropsychological testing of subjects, to allow correlation of imaging data with uniquely human aspects of the effects of drugs, such as euphoria and craving.
Keywords: human imaging, radiotracer, alcoholism, radiopharmaceutical, drug clearance, labeled drug, opioids
Current Pharmaceutical Design
Title: PET Imaging in Clinical Drug Abuse Research
Volume: 11 Issue: 25
Author(s): S. J. Gatley, N. D. Volkow, G.- J. Wang, J. S. Fowler, J. Logan, Y.- S. Ding and M. Gerasimov
Affiliation:
Keywords: human imaging, radiotracer, alcoholism, radiopharmaceutical, drug clearance, labeled drug, opioids
Abstract: Over the last two decades, SPECT (single photon emission computed tomography) and especially PET (positron emission tomography) have proven increasingly effective imaging modalities in the study of human psychopharmacology. Abusing populations can be studied at multiple times after abstinence begins, to give information about neurochemical and physiological adaptations of the brain during recovery from addiction. Individual human subjects can be studied using multiple positron labeled radiotracers, so as to probe more than one facet of brain function. PET and SPECT have been used to help our understanding of many aspects of the pharmacokinetics and pharmacodynamics of abused drugs, and have made valuable contributions in terms of drug mechanisms, drug interactions (e.g. cocaine and alcohol) and drug toxicities. They have also been employed to study the acute effects of drugs on populations of active drug abusers and of normal controls, and to evaluate the neurochemical consequences of candidate therapies for drug abuse. A particularly productive strategy has been the use of PET in conjunction with neuropsychological testing of subjects, to allow correlation of imaging data with uniquely human aspects of the effects of drugs, such as euphoria and craving.
Export Options
About this article
Cite this article as:
Gatley J. S., Volkow D. N., Wang J. G.-, Fowler S. J., Logan J., Ding S. Y.- and Gerasimov M., PET Imaging in Clinical Drug Abuse Research, Current Pharmaceutical Design 2005; 11 (25) . https://dx.doi.org/10.2174/138161205774424717
DOI https://dx.doi.org/10.2174/138161205774424717 |
Print ISSN 1381-6128 |
Publisher Name Bentham Science Publisher |
Online ISSN 1873-4286 |
Call for Papers in Thematic Issues
"Tuberculosis Prevention, Diagnosis and Drug Discovery"
The Nobel Prize-winning discoveries of Mycobacterium tuberculosis and streptomycin have enabled an appropriate diagnosis and an effective treatment of tuberculosis (TB). Since then, many newer diagnosis methods and drugs have been saving millions of lives. Despite advances in the past, TB is still a leading cause of infectious disease mortality ...read more
Current Pharmaceutical challenges in the treatment and diagnosis of neurological dysfunctions
Neurological dysfunctions (MND, ALS, MS, PD, AD, HD, ALS, Autism, OCD etc..) present significant challenges in both diagnosis and treatment, often necessitating innovative approaches and therapeutic interventions. This thematic issue aims to explore the current pharmaceutical landscape surrounding neurological disorders, shedding light on the challenges faced by researchers, clinicians, and ...read more
Emerging and re-emerging diseases
Faced with a possible endemic situation of COVID-19, the world has experienced two important phenomena, the emergence of new infectious diseases and/or the resurgence of previously eradicated infectious diseases. Furthermore, the geographic distribution of such diseases has also undergone changes. This context, in turn, may have a strong relationship with ...read more
Melanoma and Non-Melanoma Skin Cancer Treatment: Standard of Care and Recent Advances
In this thematic issue, we aim to provide a standard of care of the diagnosis and treatment of melanoma and non-melanoma skin cancer. The editor will invite authors from different countries who will write review articles of melanoma and non-melanoma skin cancers. The Diagnosis, Staging, Surgical Treatment, Non-Surgical Treatment all ...read more
- Author Guidelines
- Graphical Abstracts
- Fabricating and Stating False Information
- Research Misconduct
- Post Publication Discussions and Corrections
- Publishing Ethics and Rectitude
- Increase Visibility of Your Article
- Archiving Policies
- Peer Review Workflow
- Order Your Article Before Print
- Promote Your Article
- Manuscript Transfer Facility
- Editorial Policies
- Allegations from Whistleblowers
- Announcements
Related Articles
-
Therapeutic Potential of Group III Metabotropic Glutamate Receptors
Current Medicinal Chemistry Current Pharmaceutical Treatments and Alternative Therapies of Parkinson’s Disease
Current Neuropharmacology Novel 3-Substituted-2, 3-Dihydro-2-Thioxoquinazolin-4-(1H)-one derivative as Anticonvulsants: Synthesis, Molecular Docking and Pharmacological Screening
Letters in Drug Design & Discovery Role of the Transglutaminase Enzymes in the Nervous System and their Possible Involvement in Neurodegenerative Diseases
Current Medicinal Chemistry Editorial (Thematic Issue: Role of Antioxidants Treatments on Oxidative Stress and Calcium Entry in Neurological Disease: Focus on TRP Channels)
Current Neuropharmacology Targeting Cancer Stem Cells with Repurposed Drugs to Improve Current Therapies
Recent Patents on Anti-Cancer Drug Discovery Measuring Receptor Occupancy with PET
Current Pharmaceutical Design Pharmacotherapy and the Psychobiological Model of Personality: Implications for DSM-5
Current Psychopharmacology Anti-NMDA Receptor Encephalitis in Psychiatry
Current Psychiatry Reviews Disorders of Protein Biogenesis and Stability
Protein & Peptide Letters Proceedings of the Regional Conference of the International Society for Adolescent Psychiatry and Psychology (ISAPP), a Joint Conference with 18<sup>th</sup> National Symposium of Adolescent Mental Health, Ankara, Turkey, November 21-24, 2013<sup>1</sup>
Adolescent Psychiatry Patent Selections:
Recent Patents on Endocrine, Metabolic & Immune Drug Discovery Histamine H3 Receptor: A Potential Drug Target for the Treatment of Central Nervous System Disorders
Current Drug Targets - CNS & Neurological Disorders Immunomodulatory Properties of Antibiotics
Current Molecular Pharmacology Self-Regulatory Control and Habit Learning in the Development of Eating Disorders
Current Psychiatry Reviews Neurophysiological Alterations in the Prepsychotic Phases
Current Pharmaceutical Design Anesthetic Considerations for Electroconvulsive Therapy-Especially Hemodynamic and Respiratory Management
Current Psychiatry Reviews ABC Transporters in the Development of Multidrug Resistance in Cancer Therapy
Current Pharmaceutical Design Effects of Brain IKKβ Gene Silencing by Small Interfering RNA on P-Glycoprotein Expression and Brain Damage in the Rat Kainic Acid-Induced Seizure Model
CNS & Neurological Disorders - Drug Targets Pathogenesis of Stroke-Like Episodes in MELAS: Analysis of Neurovascular Cellular Mechanisms
Current Neurovascular Research